Warning Letters: DanChem Technologies and Medsep

Mar 10, 2005
By Pharmaceutical Technology Editors
Warning Letters: DanChem Technologies and Medsep

The US Food and Drug Administration this week released drug-product warning letters sent to DanChem Technologies (Danville, VA, www.danchem.com) and Medsep Corp. (Covina, CA).

On March 3, FDA's Baltimore (MD) District Office sent a three-page letter to DanChem, an active-pharmaceutical-ingredient maker. The letter cited "physical filth" contamination found by a customer in several lots of calcium polycarbophil. The warning also cited "significant violations of current good manufacturing practice" found during agency inspections last fall, including:
  • blending out-of-specification calcium polycarbophil with in-spec batches to bring the combined batches within specification;
  • omitting ingredient names and weights from batch records;
  • maintaining "inaccurate" disposal records by labeling, disposing of, and recording debris-filled ontainers as "rejected API";
  • failure to review batch records that indicated that the amount of material produced exceeded the capacity of the processing equipment; and
  • failure to investigate foreign material found in manufacturing equipment.

On Feb. 15, the Los Angeles District Office (Irvine, CA) sent a letter to Medsep (a subsidiary of Pall Corp., East Hills, NY, www.pall.com), dealing mainly with procedural and record-keeping shortcomings in the manufacture of bacterial detection devices used with oxygen analyzers. The inspection did note, however, that "Anticoagulant Citrate Phospahate Double Dextrose Solution with AS-3 Nuhicel Additive System" (used in blood collection bags manufactured at the same facility) are regulated under drug CGMPs, and cited inadequacies in the batch production and control records.

–Doug McCormick
lorem ipsum